FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129183114> ?p ?o ?g. }

• W3129183114 endingPage "e210369" @default.
• W3129183114 startingPage "e210369" @default.
• W3129183114 abstract "<h3>Importance</h3> There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression. <h3>Objective</h3> To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection. <h3>Design, Setting, and Participants</h3> This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020. <h3>Intervention</h3> Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care. <h3>Outcomes</h3> The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements. <h3>Results</h3> A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall<i>P</i> = .45). There was no significant difference in secondary outcomes among the treatment groups. <h3>Conclusions and Relevance</h3> In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04342728" @default.
• W3129183114 created "2021-02-15" @default.
• W3129183114 creator A5006567146 @default.
• W3129183114 creator A5012132480 @default.
• W3129183114 creator A5031582905 @default.
• W3129183114 creator A5034601007 @default.
• W3129183114 creator A5034860375 @default.
• W3129183114 creator A5069769770 @default.
• W3129183114 creator A5070324380 @default.
• W3129183114 creator A5075499171 @default.
• W3129183114 creator A5081122865 @default.
• W3129183114 creator A5083306570 @default.
• W3129183114 creator A5091775732 @default.
• W3129183114 date "2021-02-12" @default.
• W3129183114 modified "2023-10-16" @default.
• W3129183114 title "Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection" @default.
• W3129183114 cites W1966238900 @default.
• W3129183114 cites W1968459870 @default.
• W3129183114 cites W1981001019 @default.
• W3129183114 cites W2058465738 @default.
• W3129183114 cites W2090512867 @default.
• W3129183114 cites W2128825612 @default.
• W3129183114 cites W2153720904 @default.
• W3129183114 cites W2601577524 @default.
• W3129183114 cites W2611439167 @default.
• W3129183114 cites W2618198971 @default.
• W3129183114 cites W2965077788 @default.
• W3129183114 cites W3001118548 @default.
• W3129183114 cites W3008028633 @default.
• W3129183114 cites W3081594520 @default.
• W3129183114 doi "https://doi.org/10.1001/jamanetworkopen.2021.0369" @default.
• W3129183114 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7881357" @default.
• W3129183114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33576820" @default.
• W3129183114 hasPublicationYear "2021" @default.
• W3129183114 type Work @default.
• W3129183114 sameAs 3129183114 @default.
• W3129183114 citedByCount "240" @default.
• W3129183114 countsByYear W31291831142021 @default.
• W3129183114 countsByYear W31291831142022 @default.
• W3129183114 countsByYear W31291831142023 @default.
• W3129183114 crossrefType "journal-article" @default.
• W3129183114 hasAuthorship W3129183114A5006567146 @default.
• W3129183114 hasAuthorship W3129183114A5012132480 @default.
• W3129183114 hasAuthorship W3129183114A5031582905 @default.
• W3129183114 hasAuthorship W3129183114A5034601007 @default.
• W3129183114 hasAuthorship W3129183114A5034860375 @default.
• W3129183114 hasAuthorship W3129183114A5069769770 @default.
• W3129183114 hasAuthorship W3129183114A5070324380 @default.
• W3129183114 hasAuthorship W3129183114A5075499171 @default.
• W3129183114 hasAuthorship W3129183114A5081122865 @default.
• W3129183114 hasAuthorship W3129183114A5083306570 @default.
• W3129183114 hasAuthorship W3129183114A5091775732 @default.
• W3129183114 hasBestOaLocation W31291831141 @default.
• W3129183114 hasConcept C126322002 @default.
• W3129183114 hasConcept C168563851 @default.
• W3129183114 hasConcept C185592680 @default.
• W3129183114 hasConcept C187212893 @default.
• W3129183114 hasConcept C197934379 @default.
• W3129183114 hasConcept C203092338 @default.
• W3129183114 hasConcept C2986274086 @default.
• W3129183114 hasConcept C31903555 @default.
• W3129183114 hasConcept C35785553 @default.
• W3129183114 hasConcept C535046627 @default.
• W3129183114 hasConcept C71924100 @default.
• W3129183114 hasConceptScore W3129183114C126322002 @default.
• W3129183114 hasConceptScore W3129183114C168563851 @default.
• W3129183114 hasConceptScore W3129183114C185592680 @default.
• W3129183114 hasConceptScore W3129183114C187212893 @default.
• W3129183114 hasConceptScore W3129183114C197934379 @default.
• W3129183114 hasConceptScore W3129183114C203092338 @default.
• W3129183114 hasConceptScore W3129183114C2986274086 @default.
• W3129183114 hasConceptScore W3129183114C31903555 @default.
• W3129183114 hasConceptScore W3129183114C35785553 @default.
• W3129183114 hasConceptScore W3129183114C535046627 @default.
• W3129183114 hasConceptScore W3129183114C71924100 @default.
• W3129183114 hasIssue "2" @default.
• W3129183114 hasLocation W31291831141 @default.
• W3129183114 hasLocation W31291831142 @default.
• W3129183114 hasOpenAccess W3129183114 @default.
• W3129183114 hasPrimaryLocation W31291831141 @default.
• W3129183114 hasRelatedWork W2026462764 @default.
• W3129183114 hasRelatedWork W2147256274 @default.
• W3129183114 hasRelatedWork W2312635070 @default.
• W3129183114 hasRelatedWork W2321933834 @default.
• W3129183114 hasRelatedWork W2766832809 @default.
• W3129183114 hasRelatedWork W2982038996 @default.
• W3129183114 hasRelatedWork W3000734051 @default.
• W3129183114 hasRelatedWork W4232067681 @default.
• W3129183114 hasRelatedWork W4256514411 @default.
• W3129183114 hasRelatedWork W4292283255 @default.
• W3129183114 hasVolume "4" @default.
• W3129183114 isParatext "false" @default.
• W3129183114 isRetracted "false" @default.
• W3129183114 magId "3129183114" @default.
• W3129183114 workType "article" @default.